Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.

× No keyword cloud information.

15 in total

1. NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Authors: Amiram Gafni; Stephen Birch
Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981

2. The 'NICE' approach to technology assessment: an economics perspective.

Authors: Stephen Birch; Amiram Gafni
Journal: Health Care Manag Sci Date: 2004-02

3. The NICE reference case requirement: more pain for what, if any, gain?

Authors: Amiram Gafni; Stephen Birch
Journal: Pharmacoeconomics Date: 2004 Impact factor: 4.981

4. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors: Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

Review 5. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.

Authors: S D Walter; Amiram Gafni; Stephen Birch
Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981

Review 6. The NICE cost-effectiveness threshold: what it is and what that means.

Authors: Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

Review 7. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?

Authors: Heather McDonald; Cathy Charles; Laurie Elit; Amiram Gafni
Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981

8. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.

Authors: Peter A Ubel; Scott R Berry; Eric Nadler; Chaim M Bell; Michael A Kozminski; Jennifer A Palmer; William K Evans; Elizabeth L Strevel; Peter J Neumann
Journal: Health Aff (Millwood) Date: 2012-04 Impact factor: 6.301

Review 9. The role of patient preferences in cost-effectiveness analysis: a conflict of values?

Authors: John E Brazier; Simon Dixon; Julie Ratcliffe
Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981

10. Trends in parameterization, economics and host behaviour in influenza pandemic modelling: a review and reporting protocol.

Authors: Luis R Carrasco; Mark Jit; Mark I Chen; Vernon J Lee; George J Milne; Alex R Cook
Journal: Emerg Themes Epidemiol Date: 2013-05-07